Description
ARA-290 (Cibinetide)
WHAT IS ARA-290?
ARA-290, also known as Cibinetide, is a synthetic peptide derived from the tissue-protective region of erythropoietin (EPO). It was specifically engineered to support tissue repair, nerve health, and inflammation modulation without stimulating red blood cell production like traditional EPO.
ARA-290 has gained significant attention in peptide and regenerative research for its potential role in supporting nerve regeneration, reducing inflammatory signaling, improving neuropathic symptoms, and promoting cellular recovery. It works through activation of the Innate Repair Receptor (IRR), a pathway associated with tissue protection and healing.
POTENTIAL BENEFITS OF ARA-290
Nerve Support & Neuropathy Research
ARA-290 is widely researched for its potential ability to support nerve repair and reduce neuropathic discomfort. Studies have explored its role in diabetic neuropathy, small fiber neuropathy, and nerve inflammation.
Inflammation Modulation
Research suggests ARA-290 may help regulate inflammatory cytokines and reduce chronic inflammatory signaling associated with tissue damage and nerve irritation.
Tissue Protection & Recovery
ARA-290 has been studied for its potential tissue-protective effects in models involving metabolic stress, cardiovascular injury, inflammatory conditions, and cellular damage.
Cellular Repair Support
The peptide may help activate natural repair pathways associated with recovery, healing, and cellular resilience following inflammation or stress-related injury.
Non-Hematopoietic Action
Unlike erythropoietin, ARA-290 was designed to avoid increasing hematocrit or red blood cell production, reducing concerns associated with EPO-related cardiovascular risks.
HOW ARA-290 WORKS
ARA-290 selectively activates the Innate Repair Receptor (IRR), a receptor complex associated with anti-inflammatory and tissue-protective signaling pathways. This receptor becomes active during periods of injury, inflammation, or cellular stress.
Research indicates activation of this pathway may:
- Reduce inflammatory signaling
- Support nerve regeneration
- Promote tissue repair
- Improve microvascular function
- Protect cells from inflammatory damage
Unlike traditional EPO compounds, ARA-290 does not significantly stimulate erythropoiesis, making it a unique compound in regenerative peptide research.
COMMON RESEARCH APPLICATIONS
ARA-290 is commonly researched for:
- Small fiber neuropathy
- Diabetic neuropathy
- Chronic inflammation
- Tissue recovery
- Nerve regeneration
- Microvascular support
- Inflammatory pain conditions
- Recovery and regenerative protocols
Research surrounding ARA-290 continues to expand across neurological and inflammatory models.
RESEARCH DOSING INFORMATION
Common research dosage range:
- 2mg–4mg daily
Typical research administration:
- Subcutaneous injection
Common research cycle length:
- 4–8 weeks
Due to ongoing clinical investigation, standardized dosing protocols have not been officially established.
For research purposes only.
POTENTIAL SIDE EFFECTS
Human clinical data has generally reported favorable tolerability in research settings; however, research is still ongoing. Potential reported side effects may include:
- Injection site irritation
- Headache
- Fatigue
- Nausea
- Mild dizziness
Long-term human safety data remains limited.
WHY RESEARCHERS ARE INTERESTED IN ARA-290
ARA-290 stands out because it combines:
- Anti-inflammatory research potential
- Tissue-protective signaling
- Nerve support properties
- Non-hormonal activity
- Favorable preliminary safety profile
Its ability to activate repair pathways without increasing red blood cell production has made it a major focus in regenerative medicine and neuropathy research.
WHY CHOOSE OUR ARA-290?
- Premium quality peptide sourcing
- Third-party purity testing
- Sterile research-grade formulation
- Secure packaging
- Fast shipping
- Trusted by peptide researchers nationwide
FREQUENTLY ASKED QUESTIONS
Is ARA-290 a hormone?
No. ARA-290 is a synthetic peptide derived from erythropoietin’s tissue-protective region, but it does not function like a traditional hormone or anabolic compound.
Does ARA-290 increase red blood cell count?
Current research suggests ARA-290 does not significantly stimulate red blood cell production like erythropoietin.
What is ARA-290 mainly researched for?
It is most commonly researched for neuropathy, inflammation modulation, tissue protection, and nerve repair support.
How quickly does ARA-290 work?
Research timelines vary depending on the model and application. Some studies observed changes within several weeks of consistent administration.
Is ARA-290 FDA approved?
ARA-290 remains an investigational research compound and is not FDA-approved for general medical use.
IMPORTANT DISCLAIMER
ARA-290 (Cibinetide) is an investigational research compound intended strictly for laboratory and scientific research purposes only.
This product is not intended to diagnose, treat, cure, or prevent any disease.
Not for human consumption.
Keep out of reach of children.
CLICK HERE TO Contact us with any questions!
NENMASS@GMAIL.COM
508-809-3469
